As of Apr 20
| -0.0062 / -0.94%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 1.50, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a +129.57% increase from the last price of 0.65.
The current consensus among 7 polled investment analysts is to Hold stock in Regulus Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.